Annovis Bio
ANVS
23 hedge funds and large institutions have $11.6M invested in Annovis Bio in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
21% more capital invested
Capital invested by funds: $9.6M → $11.6M (+$1.99M)
0.14% more ownership
Funds ownership: 9.08% → 9.22% (+0.14%)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$240K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$223K |
| 3 |
WANY
Wealthspire Advisors (New York)
New York
|
+$161K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
+$80.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$451K |
| 2 |
BlackRock
New York
|
-$145K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$44K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$19.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| – | -$81 | -6 | Closed |
|
ANVS Hedge Fund Activity: Q1 2023 in Review
23 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2023, worth a combined $11.6M — up 21% from $9.6M a quarter earlier.
Fund positioning in ANVS was balanced in Q1 2023: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $240K. The largest seller was Morgan Stanley, cutting an estimated $451K.
- 23 institutional investors held Annovis Bio (ANVS) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $11.6M of Annovis Bio stock for Q1 2023, up 21% quarter-over-quarter.
- 4 funds opened new Annovis Bio positions in Q1 2023 and 4 closed out, a net change of 0 holders.
- The largest Annovis Bio buyer in Q1 2023 was Jane Street, an estimated $240K added.
- The largest Annovis Bio seller in Q1 2023 was Morgan Stanley, an estimated $451K sold.
Based on aggregated 13F filings for Q1 2023.